Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small Cell Lung Cancer: CANOPY-A Trial

被引：0
|
作者：
Garon, Edward B.
Ardizzoni, Andrea
Barlesi, Fabrice
Cho, Byoung Chul
De Marchi, Pedro
Goto, Yasushi
Kowalski, Dariusz
Lu, Shun
Spigel, David R.
Thomas, Michael
Yang, James Chih-Hsin
Turri, Sabine
Zhou, Wen
Kreisl, Teri
Paz-Ares, Luis
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2021年 / 20卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-21-LBA039
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA039
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Utilization of Adjuvant Therapy Among Completely Resected Non-Small Cell Lung Cancer (NSCLC) Patients at Charleston Area Medical Center
    Jubelirer, Steven J.
    Larson, Seth B.
    Welch, Christine A.
    Budhan, Zelia R.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S678 - S678
  • [32] Adjuvant chemotherapy for resected non-small cell lung cancer
    Booth, Christopher M.
    Shepherd, Frances A.
    JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (02) : 180 - 187
  • [33] Adjuvant Chemotherapy for Resected Non-Small Cell Lung Cancer
    Wakelee, Heather
    Chhatwani, Laveena
    SEMINARS IN THORACIC AND CARDIOVASCULAR SURGERY, 2008, 20 (03) : 198 - 203
  • [34] Adjuvant chemotherapy in completely resected non-small-cell lung cancer
    Pisters, KMW
    Le Chevalier, T
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (14) : 3270 - 3278
  • [35] Adjuvant Chemotherapy for Completely Resected Non-Small-Cell Lung Cancer
    Suehisa, Hiroshi
    Toyooka, Shinichi
    ACTA MEDICA OKAYAMA, 2009, 63 (05) : 223 - 230
  • [36] Adjuvant Cisplatin and Vinorelbine for Completely Resected Non-small Cell Lung Cancer Subgroup Analysis of the Lung Adjuvant Cisplatin Evaluation
    Douillard, Jean-Yves
    Tribodet, Helene
    Aubert, Delphine
    Shepherd, Frances A.
    Rosell, Rafael
    Ding, Keyue
    Veillard, Anne-Sophie
    Seymour, Lesley
    Le Chevalier, Thierry
    Spiro, Stephen
    Stephens, Richard
    Pignon, Jean Pierre
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (02) : 220 - 228
  • [37] CANOPY-A: A phase III, placebo-controlled study of canakinumab as adjuvant therapy in patients (pts) with surgically resected NSCLC
    Cho, B. C.
    Chang, G-C.
    Kim, Y-C.
    Geater, S.
    Saeteng, S.
    Yang, C-T.
    Goto, Y.
    Lu, S.
    Ardizzoni, A.
    Barlesi, F.
    De Marchi, P.
    Paz-Ares, L.
    Spigel, D. R.
    Thomas, M.
    Garon, E. B.
    Leung, M.
    Baum, J.
    Zewen, Z.
    Mookerjee, B.
    Yang, J. C-H.
    ANNALS OF ONCOLOGY, 2019, 30
  • [38] FEASIBILITY STUDY OF S-1 ADJUVANT CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED NON-SMALL CELL LUNG CANCER
    Okumura, Shunsuke
    Sasaki, Takaaki
    Minami, Yoshinori
    Kitada, Masahiro
    Ohsaki, Yoshinobu
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1327 - S1328
  • [39] Adjuvant therapy in resected non-small cell lung cancer: current status and perspectives
    Robert Pirker
    Holistic Integrative Oncology, 4 (1):
  • [40] Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program
    Filipits, Martin
    Haddad, Vincent
    Schmid, Katharina
    Huynh, Anh
    Dunant, Ariane
    Andre, Fabrice
    Brambilla, Elisabeth
    Stahel, Rolf
    Pignon, Jean-Pierre
    Soria, Jean-Charles
    Popper, Helmut H.
    Le Chevalier, Thierry
    Pirker, Robert
    CLINICAL CANCER RESEARCH, 2007, 13 (13) : 3892 - 3898
12345